RxDoctor Payments Data

Peter Kahrilas, MD

Gastroenterology · Chicago, ILNPI 1528098688

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 54.9% of the total. Reporting peaked in 2024 at $88,875 and has fallen 97.4% since, to $2,288 in 2025. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$157,046in general payments, 2019–2025

Across 167 payments — averaging $940.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$86K
  • Ironwood Pharmaceuticals, Inc$49K
  • Bayer$7K
  • Janssen Research & Development, LLC$5K
  • Astrazeneca AB$5K
  • Johnson & Johnson$4K
  • plus $656 from 7 others

What the payments were for

  • Consulting fees$64,47841%
  • Speaking & faculty fees$71,37545%
  • Travel & lodging$16,17310%
  • Food & beverage$5,0203%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,046 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$17,276
Medicare patients
91
Services billed
149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VoqueznaVonoprazan Fumarate13$24,648
Dexlansoprazole DrDexlansoprazole15$7,535
Omeprazole350$6,403
Esomeprazole Magnesium30$4,169
Rabeprazole Sodium33$1,774
Lansoprazole24$1,183
Dicyclomine Hcl20$617
Pantoprazole Sodium19$419
Ondansetron OdtOndansetron13$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Phathom Pharmaceuticals, Inc.Voquezna$86,189$24,64813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →